Literature DB >> 22360506

Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients.

Joon Seon Song1, Yong Seok Kim, Dong Kwan Kim, Sung Il Park, Se Jin Jang.   

Abstract

Global histone modification patterns are presumed to establish epigenetic patterns of gene expression and determine the biology of the cell. In the present study, the global modification status of histone H3 and H4 was evaluated in 408 non-small cell lung cancer (NSCLC) tissues by immunostaining. NSCLC showed variable staining scores for each antibody. Clinicopathological analyses demonstrated a positive correlation between weak nuclear staining for H3K9Ac (P < 0.001), H3K9TriMe (P= 0.001), H4K16Ac (P < 0.001) and tumor recurrence except H4K20 TriMe (P= 0.201). Staining scores of four different antibodies were not correlated with other clinicopathologic variables. Patients were further clustered according to histone modification patterns: acetylation dominant, methylation dominant, co-dominant and modification-negative. The acetylation-dominant group (P= 0.009) and co-dominant group exhibited less frequent lymph node metastasis (P= 0.050), recurrence (P= 0.002) and distant metastasis (P= 0.010). The acetylation-dominant group showed better prognosis in survival analysis (P < 0.001, log-rank), whereas methylation-dominant and modification-negative status was associated with poor prognosis. In conclusion, our data suggest that global histone H3 and H4 modification patterns are potential markers of tumor recurrence and disease-free survival in NSCLC patients.
© 2012 The Authors. Pathology International © 2012 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22360506     DOI: 10.1111/j.1440-1827.2011.02776.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  36 in total

1.  Histone modifications and cancer: biomarkers of prognosis?

Authors:  Yana Chervona; Max Costa
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

Review 2.  Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules.

Authors:  Pilar Blancafort; Jian Jin; Stephen Frye
Journal:  Mol Pharmacol       Date:  2012-11-13       Impact factor: 4.436

Review 3.  Redox regulation of the epigenetic landscape in cancer: a role for metabolic reprogramming in remodeling the epigenome.

Authors:  Michael J Hitchler; Frederick E Domann
Journal:  Free Radic Biol Med       Date:  2012-09-26       Impact factor: 7.376

Review 4.  Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.

Authors:  Insa Schiffmann; Gabriele Greve; Manfred Jung; Michael Lübbert
Journal:  Epigenetics       Date:  2016-11-15       Impact factor: 4.528

5.  Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation.

Authors:  Leah C Young; Darin W McDonald; Michael J Hendzel
Journal:  J Biol Chem       Date:  2013-06-06       Impact factor: 5.157

6.  Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.

Authors:  Naoimh Herlihy; Mehmet Dogrusöz; T Huibertus van Essen; J William Harbour; Pieter A van der Velden; Marja C J A van Eggermond; Geert W Haasnoot; Peter J van den Elsen; Martine J Jager
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-15       Impact factor: 4.799

Review 7.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

Review 8.  Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.

Authors:  Alice Pasini; Angelo Delmonte; Anna Tesei; Daniele Calistri; Emanuele Giordano
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

9.  A quantitative atlas of histone modification signatures from human cancer cells.

Authors:  Gary Leroy; Peter A Dimaggio; Eric Y Chan; Barry M Zee; M Andres Blanco; Barbara Bryant; Ian Z Flaniken; Sherry Liu; Yibin Kang; Patrick Trojer; Benjamin A Garcia
Journal:  Epigenetics Chromatin       Date:  2013-07-05       Impact factor: 4.954

10.  Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer.

Authors:  Fernanda S Giudice; Decio S Pinto; Jacques E Nör; Cristiane H Squarize; Rogerio M Castilho
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.